References
- Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339–1350.
- Miossec P, Kolls JK. Targeting IL-17 and Th17 cells in chronic inflammation. Drug Discov Nat Rev. 2012;11:763–776.
- Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a Th17 cytokine, mediates IL-23 induced dermal inflammation and acanthosis. Nature. 2007;455:648–651.
- Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F. Th17 cells: new players in asthma pathogenesis. Allergy. 2011;66:989–998.
- Al-Ramli W, Prefontaine D, Chouiali F, Martin JG, Olivenstein R, Hamid Q. Th17 associated cytokines (IL17A and IL17F) in severe asthma. J Allergy Clin Immunol. 2009;123:1185–1187.
- Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Rev Immunol. 2003;3:133–146.
- Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699–5708.
- Weber J, Keam SJ. Ustekinumab. Biodrugs. 2009;23:53–61.
- Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotech. 2011;29:615–624.
- Apfelbacher CJ, Jones C, Hankins M, Smith H. Validity of two common asthma-specific quality of life questionnaires: juniper mini asthma quality of life questionnaire and Sydney asthma quality of life questionnaire. Health Qual Life Outcomes. 2012;10:97.
- Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59–65.
- Schatz M, Zeiger RS, Drane A, Harden K, Cibildak A, Oosterman JE, et al. Reliability and predictive validity of the Asthma Control Test administered by telephone calls using speech recognition technology. J Allergy Clin Immunol. 2007;119:336–343.
- Fanta CH. Asthma. N Engl J Med. 2009;360:1002–1014.
- Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–1211.
- Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111:1053–1057.
- Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol. 2008;128:1064–1067.
- Tang C, Chen S, Qian H, Huang W. IL-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012;135:112–124.
- Good JT Jr, Kolakowski CA, Groshong SD, Murphy JR, Martin RJ. Refractory asthma: importance of bronchoscopy to identify phenotypes and direct therapy. Chest. 2012;141:599–606.
- Randolph AG, Lange C, Silverman EK, Lazarus R, Silverman ES, Raby B, et al. The IL12B gene is associated with asthma. Am J Hum Genet. 2004;75:709–715.
- Chen T, Liang W, Gao L, Wang Y, Liu Y, Zhang L, et al. Association of single nucleotide polymorphisms in interleukin 12 (IL-12A and –B) with asthma in a Chinese population. Hum Immunol. 2011;72:603–606.
- Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, et al. Il-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res. 2006;7:135.
- Lajoie S, Lewkowich IP, Suzuki Y, Clark JR, Sproles AA, Dienger K, et al. Complement-mediated regulation of the interleukin 17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol. 2010;11:928–935.
- Zhao J, Lloyd CM, Noble A. Th17 responses in chronic allergic airway inflammation abrogate regulatory T-cell-mediated tolerance and contribute to airway remodeling. Mucosal Immunol. 2013;6(2):335–346.
- McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, et al. Th17 cells mediate steroid resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol. 2008;181:4089–4097.
- Zimmerman DH, Taylor P, Bendele A, Carambula R, Duzant Y, Lowe V, et al. CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. Int Immunopharmacol. 2010;10:412–421.